Technology

La Jolla Pharmaceutical

$5.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-5.56%) Today
-$0.05 (-0.93%) As of 9:37 PM UTC after-hours

Why Robinhood?

You can buy or sell LJPC and other stocks, options, and ETFs commission-free!

About LJPC

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA. The listed name for LJPC is La Jolla Pharmaceutical Company Common Stock.

CEO
Larry Edwards
Employees
91
Headquarters
San Diego, California
Founded
1989
Market Cap
136.47M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
4.23M
High Today
$5.77
Low Today
$5.30
Open Price
$5.62
Volume
654.60K
52 Week High
$9.38
52 Week Low
$3.36

Collections

LJPC Earnings

-$1.12
-$0.75
-$0.37
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1, After Hours

You May Also Like

GSL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure